TL;DR
Lupin posted Q4 FY 26 revenue of about ₹7,475 crore, up 31.9% YoY with PAT soaring ~89-90% to roughly ₹1470 crore. It is driven primarily by strong U.S. and emerging markets sales and expanded EBITDA by 35%.
About Lupin Limited
Lupin Limited was founded in 1968, the company works across generics branded formulations, APIs, biotech and consumer healthcare. It is a Mumbai-based global pharmaceutical company that sells its product in over 100 countries. Lupin has strong exposure to India, the U.S. and other emerging markets.
Lupin trades on both BSE (NSE: LUPIN, BSE: 500257) and is consistently counted among the top 5-10 pharma players by prescription share in the U.S. and among the top 10 Indian pharma companies by market share.
Lupin Share Price
Source: NSE
Lupin Q4 FY 2026 Earnings: The Big Picture
Metric | Value | YoY Change | Notes |
Consolidated Revenue | 7,474.7 | +31.9% | Up from ₹5,667.1 crore in Q4 FY2025. |
Profit After Tax (PAT) | 1,468.7 | +87.7% | Up from ₹782.4 crore in Q4 FY2025; often rounded to “up ~90%” in media reports. |
EBITDA | 2,626.3 | +90.6% | EBITDA margin expanded to 35.5% from 24.8% in Q4 FY2025. |
These figures come from summarised financials by Rediff Money.
Key Financial Metrics (Q4 FY 2026 Vs Q4 FY 2025)
Here is a quick view of Q4FY 2026 line items taken from the Lupin-authored table.
Source: Lupin
Metric (₹ millions) | Q4 FY2026 | Q4 FY2025 | YoY change |
Sales (formulations + API) | 73,919 | 55,622 | |
Total Revenue from Operations | 74,747 | 56,671 | |
Gross Profit (excl. other income) | 55,403 | 38,760 | |
EBITDA | 26,263 | 13,781 | |
EBITDA margin | 35.5% | 24.8% | |
Profit Before Tax (PBT) | 19,280 | 8,958 | |
Profit After Tax (PAT) | 14,687 | 7,824 | +87.7% |
Profit for the period (incl. non‑controlling) | 14,604 | 7,725 | +89.0% |
Source: lupin
Where is The Growth Coming From: Geographic Sales Mix
A closer look at the Q4 FY 2026 sales mix shows a strong contribution from the U.S. and emerging markets. It supports the margin expansion and profitability spike reported in the Lupin share price-linked commentary. (Source: Lupin)
U.S. Region: In Q4 FY 26, there was a total revenue of ₹33,987 crore. It showed a sales growth of up 56.9% YoY, now about 46% of global sales
India Region: A total revenue ₹19,802 crore was observed, which was up 11.5% YoY, approximately 26% of global sales.
Emerging Market: For these markets, a total revenue of ₹9,906 crore was registered, up 49.2% YoY around 13% of global sales.
Lupin attributes this growth to strong prescription level performance in the U.S. generics market and selective brand launches in India and the outside market.
Conclusion
Lupin’s Q Fy 2026 results paint a clear picture of a turnaround-to-growth story fully in motion: profit up by nearly 90%, revenue touching ₹7500 crore. This is all driven by U.S. generics market and improving India and emerging business markets.
The declaration of record dividend is management’s confidence in future cash flow and its commitment to rewarding shareholders.
These results reinforce stock as large cap domestic pharma play with improving balance sheets. The investors need to watch sustained margin performance, competitive dynamics in the U.S., and how does the execution in emerging markets including India.
FAQs
How much is the total profit and revenue registered in Q4 FY 26 for Lupin?
Lupin reported a consolidated revenue of ₹7,474.7 crore. This is about 31.9% up YoY. Other than this, a PAT of ₹1,468.7 crore in Q4 FY 2026.
Where can I quickly verify or check quarterly results of Lupin?
You can check the official figures at Lupin’s website here.
What is Lupin’s share price and where is it listed?
Lupin is listed on NSE as LUPIN and 500257 on the BSE. The data shows the stock price is ₹2,300-₹2,400 band.
Why is Lupin’s dividend the highest ever?
Lupin’s FY 26 profit after tax jumped over 60% YoY to ₹53,555 crore with Q4 PAT up ~87-90% . Other than this, EBITDA margins extended sharply to the mid 30% range, improving operating cash generation. The board’s confidence of 900% at ₹18 dividend is framed as a shareholder friendly signal that management is confident about profitability and cash flow.
